Webinars

Sekisui XenoTech

LabTube.tv
  • settings
  • CC
  • 360p
  • 480p
  • 720p
  • 1080p
373 VIEWS | 1 LIKES

Suicide by Binding: Putting Time-Dependent Inhibition of CYP Enzymes into Perspective

Sekisui XenoTech

Webinar Presenter: Brian Ogilvie, Ph.D., SEKISUI XenoTech Vice President of Scientific Consulting with special guest for Q&A, Lois Haupt, SEKISUI XenoTech Principal Scientist in Program Oversight

Many drug candidates are screened out in discovery due to a time-dependent cytochrome P450 (CYP) enzyme inhibition signal in an in vitro IC50 shift assay because time-dependent inhibition (TDI) is often of greater clinical concern than direct inhibition. Depending on the drug target or intended indications, this approach may be akin to throwing the baby out with the bathwater.

Numerous successful drugs cause TDI of CYP enzymes such as fluoxetine, gemfibrozil, esomeprazole, clopidogrel, etc. TDI may be reversible if it is caused by a metabolite that is simply a more potent inhibitor than the parent is, or irreversible. Irreversible time-dependent inhibition may be the result of mechanism-based inactivation, sometimes known as “suicide inhibition.” There are also several types of apparently irreversible inhibition-- an experimental approach that distinguishes these types from true mechanism-based inhibition can be important. Even in cases where the TDI is due to mechanism-based inhibition, the extent of inactivation may not be sufficient to cause clinically relevant drug-drug interactions (DDIs), or if they do, the risk can be managed through labelling or dosage adjustments.

Key concepts discussed in the webinar:
- In vitro approaches to evaluate time-dependent inhibition, including determination of IC50 shifts, KI and kinact values
- Methods to distinguish reversible from irreversible TDI
- Approaches to predicting clinical DDIs resulting from reversible or irreversible TDI
- Case examples

Download slides: https://www.xenotech.com/access-adme-research-resources/resources/suicide-by-binding-putting-time-dependent-inhibition-of-cyp-enzymes-into-perspective/?emat=1020LT
Questions, comments and requests: https://www.xenotech.com/contact/?emat=1020LT
More information on our research services and test systems: https://www.xenotech.com/?emat=1020LT
Other previously aired webinars: https://www.xenotech.com/access-adme-research-resources/resource-type/webinar/?emat=1020LT
Upcoming webinar notifications: https://www.xenotech.com/contact/newsletter-sign-up/?emat=1020LT
Request a webinar topic: https://www.xenotech.com/contact/webinar-seminar-request/?emat=1020LT

About the presenters
Dr. Brian Ogilvie currently serves as Vice President of Scientific Consulting at SEKISUI XenoTech. Brian joined XenoTech in 1997, and obtained his Ph.D. in toxicology from the University of Kansas Medical Center and B.A. in molecular biology from William Jewell College. Brian is an author or coauthor on over 50 scientific posters, peer-reviewed publications and book chapters on the topics of drug metabolism, transport and drug-drug interactions, and has represented the company as an invited speaker at various drug metabolism conferences. As VP of the Consulting Department, he leads drug-drug interaction-related R&D projects, authors various publications, writes expert opinions for consulting clients, and oversees all consultancy services.

Lois Haupt will join Dr. Ogilvie for the live Q&A following the presentation. Lois celebrates her 20th year with SEKISUI XenoTech this summer, beginning as a Scientist I in the Enzyme Inhibition service group and working her way up to Principal Scientist in Program Oversight. Her expertise spans drug metabolism research and regulatory compliance, and her specific area of expertise encompasses CYP and UGT inhibition assays along with data interpretation and follow-up to these studies.

about 1 month ago

Other Videos In This Playlist

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy